Alan Fuhrman

Alan Fuhrman is currently Director at Life Science Washington, Director at SpringWorks Therapeutics LLC since 2019, and Chief Financial Officer at Tyra Biosciences, Inc. starting in 2026.
Former roles include Independent Director at Springworks Therapeutics, Inc. from 2019 to 2025, Independent Director at Loxo Oncology, Inc. from 2015 to 2019, Independent Director at Checkmate Pharmaceuticals, Inc. in 2022, Independent Director at Esperion Therapeutics, Inc., Chief Financial Officer & Senior Vice President at Sonus Pharmaceuticals, Inc. from 2004 to 2008, Chief Financial Officer at NeoPath, Inc., Chief Financial Officer & Vice President at Naviscan, Inc. from 2008 to 2010, Chief Financial Officer at Capital Stream, Inc. in 2002, President & Chief Operating Officer at Integrex, Inc. in 2004, Chief Financial Officer at Medisystems Corp., CFO & Principal Accounting Officer at Mirna Therapeutics, Inc. from 2015 to 2017, Chief Financial Officer at Amplyx Pharmaceuticals, Inc. from 2017 to 2020, and Chief Financial Officer at Ambit Biosciences Corp.
from 2010 to 2014.
Education includes undergraduate studies at Montana State University.